论文部分内容阅读
BACKGOURND BRCA1 expression differentially affects outcome to platinum-and taxanebased chemotherapy.MDC1,53BP1,MMSET and UBC9 are involved in DNA repair and could modify the BRCA1 predictive model.MOTHODS MDC1,53BP1,MMSET and UBC9 mRNA was assessed in gastric tumors from patients in whom BRCA1 levels had previously been determined.RESULTS In vitro chemosensitivity assay,MMSET levels were higher in docetaxel-sensitive samples.In a separate cohort,survival was longer in those with low MMSET(12.3 vs 8.8 months;P=0.04)or UBC9(12.4 vs 8.8 months;P=0.01)in patients receiving only FOLFOX.Conversely,among patients receiving second-line docetaxel,longer survival was associated with high MMSET(19.1 vs 13.9 months;P=0.003).Patients with high MMSET and BRCA1 attained a median survival of 36.6 months,compared to 13.9 months for those with high BRCA1 and low MMSET(P=0.003).In the multivariate analyses,low MMSET(HR,0.59;P=0.04)and low UBC9(HR,0.52;P=0.01)levels were markers of longer survival to first-line FOLFOX,while palliative surgery(HR,2.47,P=0.005),low BRCA1(HR,3.17,P=0.001),and low MMSET(HR,2.52,P=0.004)levels were markers of shorter survival to second-line docetaxel.CONCLUSIONS BRCA1,MMSET and UBC9 can be useful for customizing chemotherapy in gastric cancer patients.